ArticlePsychopharmacology2025
Treatment response to bupropion: an investigation of changes in resting-state functional connectivity in patients with major depressive disorder.
Article in Psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleBupropion’s unique pharmacology as a dopaminergic and noradrenergic reuptake inhibitor distinguishes it from other antidepressants. Studies on a number of other antidepressants have demonstrated modulation of resting-state functional connectivity (rsFC). However, how bupropion affects rsFC in patients with major depressive disorder (MDD) remains unknown.
objectivesTo identify rsFC changes in MDD patients receiving bupropion treatment relative to a sample of controls.
methodThirty-nine MDD patients received 300 mg (titrated from 150 mg) Bupropion daily for 6 weeks. 40 controls received no treatment. All participants underwent MRI scans at baseline and after 2 weeks. Mood and symptom severity were assessed at baseline, week 2, and week 6. Comparisons of rsFC were made at baseline and for changes from baseline to the 2-week follow-up. Correlations between symptoms and rsFC were also assessed.
resultsIn this explorative study, no significant baseline differences were found between patients and controls. Crossover interaction effects between groups and time were observed. Network analysis identified changed rsFC between the cerebellar network and left superior and middle temporal gyrus. Seed analysis showed changed rsFC between the insula and areas in the sensorimotor and occipital cortex as well as precuneus. No relationships were found between changes in symptoms at week 6 and rsFC changes at week 2.
conclusionsThis study is the first to examine bupropion’s effects on rsFC in MDD patients, revealing rsFC changes that may be important for bupropion’s mode of action. These preliminary findings provide a foundation for further investigation into bupropion and its underlying mechanisms, which may have important implications for depression treatment.
Indexed as
Identifiers
41432737What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.